Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study

Annals of Oncology

Volumn 20, Issue 6, 2009, Pages 1042-1047

  Bidard, F C ^a   Tournigand, C ^a   Andre T ^b   Mabro, M ^c   Figer, A ^d   Cervantes, A ^e   Lledo, G ^f   Bengrine Lefevre, L ^a   Maindrault Goebel, F ^a   Louvet, C ^a   De Gramont, Aimery ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c FOCH HOSPITAL   (France)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e UNIVERSITY OF VALENCIA   (Spain)

^f Clinique Saint Jean   (France)

Author keywords

FOLFIRI 1; FOLFIRI 3; Irinotecan; Metastatic colorectal cancer; Second line chemotherapy

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; RALTITREXED;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 66149157842     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn730     Document Type: Article

References (19)

1. Jemal A, Thomas A, Murray T et al. Cancer statistics. CA Cancer J Clin 2002; 52: 23-47.
2. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
3. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
4. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
5. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
6. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
7. Cunningham D, Pyrhönen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
8. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
9. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
10. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319.
11. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.
12. Mullany S, Svingen PA, Kaufmann SH et al. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998; 42: 391-399.
13. Guichard S, Cussac D, Hennebelle I et al. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 1997; 73: 729-734.
14. Mans DR, Grivicich I, Peters GJ et al. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 1999; 35: 1851-1861.
15. Falcone A, Di Paolo A, Masi G et al. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 2001; 19: 3456-3462.
16. Mabro M, Louvet C, André T et al. Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 2003; 26: 254-258.
17. Mabro M, Artru P, André T et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006; 94: 1287-1292.
18. Viel E, Demarchi MF, Chaigneau L et al. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. Am J Clin Oncol 2008; 31: 89-94.
19. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006; 24: 394-400.